Análisis farmacoeconómico de Metoject en el tratamiento de la artritis reumatoide en España

July 2010
Reumatologia Clinica;jul/ago2010, Vol. 6 Issue 4, p203
Academic Journal
No abstract available.


Related Articles

  • Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values. Dunlop, William; Iqbal, Itrat; Khan, Ifty; Ouwens, Mario; Heron, Louise // ClinicoEconomics & Outcomes Research;2013, Vol. 5, p555 

    Background: Assessing the cost-effectiveness of treatments in rheumatoid arthritis (RA) is of growing importance due to the chronic nature of the disease, rising treatment costs, and budget-constrained health care systems. This analysis assesses the cost-effectiveness of modified-release (MR)...

  • Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. Mittendorf, T.; Dietz, B.; Sterz, R.; Cifaldi, M. A.; Kupper, H.; Schulenburg, J.-M. von der // Rheumatology;Feb2008, Vol. 47 Issue 2, p188 

    Objectives. This study evaluated the patients’ perspective of burden of disease among 505 patients with severe, long-standing rheumatoid arthritis receiving adalimumab.

  • The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis. Welsing, Paco M. J.; Severens, Johan L.; Hartman, Margriet; van Gestel, Anke M.; van Riel, Piet L. C. M.; Laan, Roland F. J. M. // PharmacoEconomics;2006, Vol. 24 Issue 10, p1011 

    Objective: Markov models are increasingly used in economic evaluations of (new) treatments for chronic diseases. In this study we propose a Markov model with health states defined by the disease activity score (DAS) to be used to extrapolate efficacy data from short-term clinical...

  • Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: A Markov model based on data from Serbia, country in socioeconomic transition. Kostić, Marina; Jovanović, Snežana; Tomović, Marina; Popović Milenković, Marija; Janković, Slobodan M. // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Feb2014, Vol. 71 Issue 2, p144 

    Background/Aim. Recent studies have shown that biological treatments for rheumatoid arthritis can change the course of rheumatoid arthritis and improve functional ability of patients with rheumatoid arthritis. In spite of this fact, use of biological therapy is still limited by high prices of...

  • Glucocorticoids: greater AE costs.  // Reactions Weekly;7/16/2005, Issue 1060, p4 

    The article discusses research on healthcare costs associated with the use of glucocorticoids. Researchers developed a Markov model to evaluate the healthcare costs incurred by patients with rheumatoid arthritis who use glucocorticoids. The study shows that glucocorticoid users incurred higher...

  • Quality-of-Life Assessment in Rheumatoid Arthritis. Russell, Anthony S. // PharmacoEconomics;2008, Vol. 26 Issue 10, p831 

    Rheumatoid arthritis (RA) is a chronic and lifelong autoimmune disorder that results in significant pain, disability and excess mortality if untreated or inadequately treated. Quality-of-life (QOL) assessments are particularly important in the absence of a cure for RA. Generic and...

  • What RA treatment gives the BeSt value for money?  // PharmacoEconomics & Outcomes News;4/18/2009, Issue 576, p10 

    The article discusses research being done on the cost effectiveness of infliximab for rheumatoid arthritis (RA) treatment. It references a study by W. B. Van Den Hout and colleagues, published in the 2009 issue of "Arthritis and Rheumatism." The cost-utility study found that initial combination...

  • Ankylosing spondylitis costly in South Korea.  // PharmacoEconomics & Outcomes News;Mar2014, Vol. 698 Issue 1, p3 

    The article discusses the results of a study which showed that South Korean patients with ankylosing spondylitis (AS) are experiencing higher cost of illness (COI )and health-related quality of life (HRQOL) than patients with rheumatoid arthritis (RA). It references a research published in the...

  • Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. Tanaka, Eiichi; Hoshi, Daisuke; Igarashi, Ataru; Inoue, Eisuke; Shidara, Kumi; Sugimoto, Naoki; Sato, Eri; Seto, Yohei; Nakajima, Ayako; Momohara, Shigeki; Taniguchi, Atsuo; Tsutani, Kiichiro; Yamanaka, Hisashi // Modern Rheumatology (Springer Science & Business Media B.V.);Jul2013, Vol. 23 Issue 4, p742 

    Objectives: Our goal was to determine the annual direct medical and nonmedical costs for the care of patients with rheumatoid arthritis (RA) using data from a large cohort database in Japan. Methods: Direct medical costs [out of pocket to hospitals and pharmacies and for complementary and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics